Key role of nuclear medicine in seeking biomarkers of Huntington’s disease




We thank the European Huntington’s Disease (EURO-HD) Network, all patients and their families (Associazione Italiana Corea di Huntington-Neuromed) and the Italian Society of Hospital Neurologists (SNO, ‘lascito Gobessi’) for their support to FS.


  1. 1.
    A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell 1993;72:971–83.CrossRefGoogle Scholar
  2. 2.
    Squitieri F, Gellera C, Cannella M, Mariotti C, Cislaghi G, Rubinsztein DC, et al. Homozygosity for CAG mutation in Huntington disease is associated with a more severe clinical course. Brain 2003;126:946–55.CrossRefPubMedGoogle Scholar
  3. 3.
    Quarrell WJ, Brewer H, Squitieri F, Barker RA, Nance MA, Landwehrmeyer GB. Juvenile Huntington’s disease and other trinucleotide repeat disorders. Oxford: Oxford University Press; 2009. p. 224.Google Scholar
  4. 4.
    Marder K, Zhao H, Myers RH, Cudkowicz M, Kayson E, Kieburtz K, et al. Rate of functional decline in Huntington’s disease. Huntington Study Group. Neurology 2000;54:452–8.PubMedGoogle Scholar
  5. 5.
    Squitieri F, Cannella M, Simonelli M, Sassone J, Martino T, Venditti E, et al. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington’s disease. CNS Neurosci Ther 2009;15:1–11.CrossRefPubMedGoogle Scholar
  6. 6.
    Guidelines for the molecular genetics predictive test in Huntington’s disease. International Huntington Association (IHA) and the World Federation of Neurology (WFN) Research Group on Huntington’s Chorea. Neurology 1994;44:1533–6.Google Scholar
  7. 7.
    Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, et al. A worldwide study of the Huntington’s disease mutation. The sensitivity and specificity of measuring CAG repeats. N Engl J Med 1994;330:1401–6.CrossRefPubMedGoogle Scholar
  8. 8.
    Squitieri F, Andrew SE, Goldberg YP, Kremer B, Spence N, Zeisler J, et al. DNA haplotype analysis of Huntington disease reveals clues to the origins and mechanisms of CAG expansion and reasons for geographic variations of prevalence. Hum Mol Genet 1994;3:2103–14.CrossRefPubMedGoogle Scholar
  9. 9.
    Bonelli RM, Hofmann P. A systematic review of the treatment studies in Huntington’s disease since 1990. Expert Opin Pharmacother 2007;8:141–53.CrossRefPubMedGoogle Scholar
  10. 10.
    Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 2000;101:57–66.CrossRefPubMedGoogle Scholar
  11. 11.
    Penney Jr JB, Young AB, Shoulson I, Starosta-Rubenstein S, Snodgrass SR, Sanchez-Ramos J, et al. Huntington’s disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990;5:93–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Unified Huntington’s Disease Rating Scale: reliability and consistency. Huntington Study Group. Mov Disord 1996;11:136–42.CrossRefGoogle Scholar
  13. 13.
    Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, et al. Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791–801.CrossRefPubMedGoogle Scholar
  14. 14.
    Quarantelli M, Ciarmiello A, Morra VB, Orefice G, Larobina M, Lanzillo R, et al. Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load. Neuroimage 2003;18:360–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Weaver KE, Richards TL, Liang O, Laurino MY, Samii A, Aylward EH. Longitudinal diffusion tensor imaging in Huntington’s disease. Exp Neurol 2009;216:525–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Rosas HD, Lee SY, Bender AC, Zaleta AK, Vangel M, Yu P, et al. Altered white matter microstructure in the corpus callosum in Huntington’s disease: implications for cortical “disconnection”. Neuroimage 2010;49:2995–3004.CrossRefPubMedGoogle Scholar
  17. 17.
    Ciarmiello A, Cannella M, Lastoria S, Simonelli M, Frati L, Rubinsztein DC, et al. Brain white-matter volume loss and glucose hypometabolism precede the clinical symptoms of Huntington’s disease. J Nucl Med 2006;47:215–22.PubMedGoogle Scholar
  18. 18.
    Carrió I. Key role of nuclear medicine in bringing imaging biomarkers into clinical practice. Eur J Nucl Med Mol Imaging 2009;36:1937–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Feigin A, Tang C, Ma Y, Mattis P, Zgaljardic D, Guttman M, et al. Thalamic metabolism and symptom onset in preclinical Huntington’s disease. Brain 2007;130(Pt 11):2858–67.CrossRefPubMedGoogle Scholar
  20. 20.
    van der Burg JM, Björkqvist M, Brundin P. Beyond the brain: widespread pathology in Huntington’s disease. Lancet Neurol 2009;8:765–74.CrossRefPubMedGoogle Scholar
  21. 21.
    Squitieri F, Falleni A, Cannella M, Orobello S, Fulceri F, Lenzi P, et al. Abnormal morphology of peripheral cell tissues from patients with Huntington disease. J Neural Transm 2010;117:77–83.CrossRefPubMedGoogle Scholar
  22. 22.
    Ross CA, Shoulson I. Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics. Parkinsonism Relat Disord 2009;15 Suppl 3:S135–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR, International Huntington’s Disease Collaborative Group. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet 2004;65:267–77.CrossRefPubMedGoogle Scholar
  24. 24.
    Petrasch-Parwez E, Nguyen HP, Löbbecke-Schumacher M, Habbes HW, Wieczorek S, Riess O, et al. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease. J Comp Neurol 2007;501:716–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Chaturvedi RK, Adhihetty P, Shukla S, Hennessy T, Calingasan N, Yang L, et al. Impaired PGC-1alpha function in muscle in Huntington’s disease. Hum Mol Genet 2009;18:3048–65.CrossRefPubMedGoogle Scholar
  26. 26.
    Runne H, Kuhn A, Wild EJ, Pratyaksha W, Kristiansen M, Isaacs JD, et al. Analysis of potential transcriptomic biomarkers for Huntington’s disease in peripheral blood. Proc Natl Acad Sci U S A 2007;104(36):14424–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005;171:1001–12.CrossRefPubMedGoogle Scholar
  28. 28.
    Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, et al. Microglial activation in presymptomatic Huntington’s disease gene carriers. Brain 2007;130:1759–66.CrossRefPubMedGoogle Scholar
  29. 29.
    Gauthier LR, Charrin BC, Borrell-Pagès M, Dompierre JP, Rangone H, Cordelières FP, et al. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004;118:127–38.CrossRefPubMedGoogle Scholar
  30. 30.
    Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science 2001;293:493–8.CrossRefPubMedGoogle Scholar
  31. 31.
    Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J Exp Med 2008;205:1869–77.CrossRefPubMedGoogle Scholar
  32. 32.
    Ciammola A, Sassone J, Cannella M, Calza S, Poletti B, Frati L, et al. Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington’s disease patients. Am J Med Genet B Neuropsychiatr Genet 2007;144B(4):574–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Battaglia G, Cannella M, Riozzi B, Orobello S, Maat-Schieman ML, Aronica E, et al. Early defect of transforming growth factor beta-1 formation in Huntington’s disease. J Cell Mol Med 2010 Jan 15. [Epub ahead of print].Google Scholar
  34. 34.
    Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, et al. Cerebral cortex and the clinical expression of Huntington’s disease: complexity and heterogeneity. Brain 2008;131:1057–68.CrossRefPubMedGoogle Scholar
  35. 35.
    Reading SA, Dziorny AC, Peroutka LA, Schreiber M, Gourley LM, Yallapragada V, et al. Functional brain changes in presymptomatic Huntington’s disease. Ann Neurol 2004;55:879–83.CrossRefPubMedGoogle Scholar
  36. 36.
    Squitieri F, Orobello S, Cannella M, Martino T, Romanelli P, Giovacchini G, et al. Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging 2009;36:1113–20.CrossRefPubMedGoogle Scholar
  37. 37.
    Maglione V, Cannella M, Martino T, De Blasi A, Frati L, Squitieri F. The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington’s disease patients with predominant chorea. Neurosci Lett 2006;393:27–30.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.Neurogenetics and Rare Diseases CentreIRCCS NeuromedPozzilli (IS)Italy

Personalised recommendations